An innovation for minimally invasive ablation
K9 is an active pipeline development program by Koya that aims to provide a minimally invasive ablation solution that is clinically effective while improving the overall patient experience and accessibility.
A FDA-cleared wearable compression treatment indicated for the treatment of lymphedema, phlebolymphedema, venous insufficiency, lipedema, related conditions to chronic edema and supports mobility during treatment1.
Multiple randomized controlled studies including NILE (2022) and TEAYS (2024) showed that Dayspring provides superior outcomes in edema reduction, quality of life, and adherence compared to standard of care2,3.
Chronic Venous Insufficiency (CVI) is caused by prolonged venous hypertension, valve dysfunction, obstruction or muscle pump failure. This condition results in venous reflux and impaired venous return. Persistent pressure causes capillary leakage, inflammation, and progressive tissue damage, contributing to edema, skin changes, and venous ulcers.
Learn more about our commitment to bring solutions that address unmet and undermet needs across the venous and lymphatic continuum.
.avif){kind=logo}
